ArticlePloS one2026
Unveiling the role of interleukin-13 in liver fibrosis of chronic hepatitis B patients: Development of a predictive model.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeveloping a non-invasive model is essential for assessing liver stiffness in conditions without transient elastography, which will determine further management in chronic hepatitis B (CHB) patients.
objectivesThis study aims to evaluate the interleukin-13 role in liver fibrosis and develop a new predictive model that includes interleukin-13 and standard data such as age and platelet count.
methodsPatients were recruited from Hasan Sadikin General Hospital's CHB registry from October 2021 to January 2022. Patients underwent demographic data collection, complete blood count, interleukin-13, and transient elastography examinations on the same day. The platelet count variable was listed in ×109/ dL, and the interleukin-13 in pg/mL. Interleukin-13 values were categorized as positive for IL-13 with a cut-off of 5 pg/mL (ILcut5). The liver stiffness measurement was inverted to obtain a normal distribution and became inverseLSM as the model's outcome. The prediction model was formed through multiple linear regression analysis. RESULTS AND DISCUSSION: The number of patients studied was 88. A prediction model for inverseLSM was formulated, had an R2 of 0.37, and consisted of age, platelet count, and ILcut5 with correlation coefficients of -0.221, 0.326, and -0.288, respectively. The model had no autocorrelation, multicollinearity, or significant outliers, a normal distribution appearance, and met the homoscedastic criterion. Elevated IL-13, decreased platelet count, and aging are linked to increased liver stiffness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.